Abstract
The benzopyranopyrrole S33084 displayed pronounced affinity (pKi = 9.6) for cloned human hD3-receptors, and >100-fold lower affinity for hD2 and all other receptors (>30) examined. S33084 concentration dependently, potently, and competitively (pA2 = 9.7) antagonized dopamine (DA)-induced [35S]guanosine-5′-O-(3-thio)triphosphate (GTPγS) binding at hD3-receptors. It also concentration dependently abolished stimulation by DA of hD3-receptor-coupled mitogen-activated protein kinase. Administered alone, S33084 did not modify dialysate levels of DA in the frontal cortex, nucleus accumbens, or striatum of freely moving rats, nor the firing rate of ventrotegmental dopaminergic cell bodies. Furthermore, it had minimal effect on DA turnover in mesocortical, mesolimbic, and nigrostriatal projection regions. However, S33084 dose dependently blocked the suppressive influence of the preferential D3-agonist PD128,907 on frontocortical release of DA. Furthermore, it likewise antagonized the inhibitory influence of PD128,907 on the electrical activity of ventrotegmental dopaminergic neurons. Although less potent than S33084, GR218,231 likewise behaved as a selective hD3- versus hD2-receptor antagonist and its neurochemical and electrophysiological profiles were similar. In contrast, L741,626 was a preferential antagonist at hD2 versus hD3sites. In vivo, on administration alone, L741,626 increased frontocortical, mesolimbic, and (more potently) striatal DA release, enhanced the firing rate of dopaminergic perikarya, and accelerated cerebral DA synthesis. It also blocked the actions of PD128,907. In conclusion, S33084 is a novel, potent, selective, and competitive antagonist at hD3-receptors. Although GR218,231 behaves similarly, L741,626 is a preferential D2-receptor antagonist. DA D2- but not D3-(auto) receptors tonically inhibit ascending dopaminergic pathways, although the latter may contribute to phasic suppression of DA release in frontal cortex.
Footnotes
-
Send reprint requests to: Dr. Mark J. Millan, Institut de Recherches Servier, Centre de Recherches de Croissy, Psychopharmacology Department, 125 Chemin de Ronde, 78290 - Croissy-sur-Seine, France.
- Abbreviations:
- DA
- dopamine
- L741,626
- 4-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)piperidin-4-ol
- 7-OH-DPAT
- 7-hydroxy-2-dipropylaminotetralin
- 5-HT
- 5-hydroxytryptamine (serotonin)
- MAP
- mitogen-activated protein
- GR218,231
- 2(R,S)-(di-n-propylamino)-6-(4-methoxyphenylsulfonyl methyl)-1,2,3,4-tetrahydronaphthalene
- S33084
- (3aR, 9bS)-N-[4-(8-cyano-1,3a,4,9b-tetrahydro-3H-benzopyrano[3,4-c]pyrrole-2-yl)-butyl]-(4-phenyl) benzamide
- GTPγS
- guanosine-5′-O-(3-thio)triphosphate
- CHO
- Chinese hamster ovary
- ERK
- extracellular signal receptor-activated kinase
- VTA
- ventrotegmental area
- NA
- noradrenaline
- 5-HTP
- 5-hydroxytryptophan
- DOPAC
- dihydroxyphenylalaninecarboxylic acid
- FCX
- frontal cortex
- PD128,907
- (+)-(4aR,10bR)-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol
- U99194
- (5,6-dimethoxy-indan-2-yl)dipropylamine
- GR103,691
- 4′-acetyl-N-{4-[(2-methoxy-phenyl)-piperazin-1-yl]-butyl}-biphenyl-4-carboxamide
- S14297
- (+)-[7-(N-N-dipropylamino)-5,6,7,8-tetrahydro-naphto(2,3b)dihydro-2,3-furane]
- NSD1015
- m-hydroxybenzylhydrazine
- Received October 25, 1999.
- Accepted February 21, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|